COST-UTILITY ANALYSIS OF SOFOSBUVIR FOR TREATMENT OF GENOTYPE2 CHRONIC HEPATITIS C IN JAPAN

被引：1
|
作者：
Igarashi, A. [1 ]
Tang, W. [1 ]
Cure, S. [2 ]
Guerra, I [2 ]
Lopresti, M. [3 ]
Tsutani, K. [1 ]
机构：
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan
[2] OptumInsight, Uxbridge, Middx, England
[3] Junicon Japan Inc, Minato Ku, Tokyo, Japan
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.827
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI30
引用
收藏
页码：A368 / A368
页数：1
相关论文
共 50 条
  • [41] COST-UTILITY ANALYSIS OF TIOTROPIUM, MEDICINE FOR CHRONIC OBSTRACTIVE PULMONARY DISEASES (COPD), IN JAPAN
    Igarashi, A.
    Kato, Y.
    Makita, H.
    Fukuda, T.
    Nishimura, M.
    Tsutani, K.
    VALUE IN HEALTH, 2010, 13 (03) : A200 - A200
  • [42] Cost-effectiveness of Daclatasvir in Combination with Sofosbuvir for the Treatment of Subjects with Genotype 3 Chronic Hepatitis C Infection in the United States
    Thibault, Catherine St-Laurent
    Moorjaney, Divya
    Ganz, Michael
    Sill, Bruce E.
    Hede, Shalini
    Yuan, Yong
    Kalsekar, Anupama
    Gorsh, Boris
    HEPATOLOGY, 2015, 62 : 923A - 923A
  • [43] Treatment of Chronic Hepatitis C Genotype 2 With Simeprivir Plus Sofosbuvir With or Without Ribavirin in Veterans With and Without Cirrhosis
    Haglund, Jennifer
    Ellis, Diane
    Awad, Joseph
    GASTROENTEROLOGY, 2016, 150 (04) : S1104 - S1104
  • [44] Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States
    Thibault, Catherine Saint-Laurent
    Moorjaney, Divya
    Ganz, Michael L.
    Sill, Bruce
    Hede, Shalini
    Yuan, Yong
    Gorsh, Boris
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (07) : 692 - 702
  • [45] COST-EFFECTIVENESS OF TREATING CHRONIC HEPATITIS C GENOTYPE-1 WITH LEDIPASVIR AND SOFOSBUVIR IN GERMANY
    Stahmeyer, J. T.
    Rossol, S.
    Bert, F.
    Guerra, I. M.
    Krauth, C.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S642 - S643
  • [46] Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase
    Warren, E
    Ward, S
    Gordois, A
    Scuffham, P
    CLINICAL THERAPEUTICS, 2004, 26 (11) : 1924 - 1933
  • [47] Ledipasvir/Sofosbuvir in the Treatment of Hepatitis C Virus Genotype 6
    Nguyen, Andrew A.
    Weisberg, Ilan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S368 - S368
  • [48] COST-UTILITY ANALYSIS OF NEW ANTIVIRAL TREATMENTS FOR NON-GENOTYPE 1 HEPATITIS C VIRUS IN CHINA: A SOCIETAL PERSPECTIVE
    Wei, X.
    Yang, L.
    VALUE IN HEALTH, 2020, 23 : S174 - S174
  • [49] The efficacy of sofosbuvir and ribavirin in patients with chronic hepatitis C virus genotype 2 infection
    Kwan, Byung Soo
    Shim, Sang Goon
    Yu, Kil Jong
    Cho, Dae Hyeon
    Oh, Ji Eun
    Jeong, Chang Wook
    Kim, Kwang Min
    Lee, Hyoun Soo
    Lee, Jung Won
    Lee, Dong Kyu
    Choi, Ik Sung
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 439 - 439
  • [50] Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1
    Kumari, Radhika
    Nguyen, Mindie H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (05) : 739 - 748
12345